本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上市公司行业信息披露指引第十三号——化工》、《关 于做好主板上市公司 2025 年半年度报告披露工作的重要提醒》的要求，广东天 安新材料股份有限公司（以下简称"公司"）现将 2025 年半年度高分子复合饰 面材料业务主要经营数据披露如下： 二、高分子复合饰面材料主要产品的价格变动情况（不含税） | 主要产品 | 2025 | 年 1-6 | 月平均售 | 2024 | 年 1-6 | 月平均 | 半年度均 价同比变 | 季度均价环比 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 价 | | | 售价 | | 动比率（%） | 变动比率（%） | | | 家居装饰 | | 23,184.42 | 元/吨 | | 25,292.04 | 元/吨 | -8.33 | | -1.15 | | 饰面材料 | | | | | | | | | | 一、2025 年 1-6 月高 ...

Core Viewpoint - The article discusses an innovative method for chemically recycling mixed plastic waste into valuable chemical products, addressing the environmental challenges posed by plastic waste [2][3]. Group 1: Research Overview - The research, published in Nature, presents a strategy to convert eight common types of plastic waste into their original chemical components or other valuable compounds [3][10]. - The method focuses on identifying functional groups in mixed plastic waste to facilitate the separation and conversion of these materials into useful products [5][8]. Group 2: Methodology - The research team developed a solid-state NMR method to accurately identify the types of plastics present in the mixed waste, which is crucial for the subsequent processing steps [5][6]. - By using selective solvents, the team was able to dissolve and separate specific plastics from the mixed waste, followed by catalytic processes to convert these plastics into valuable products [6][7]. Group 3: Results and Innovations - The study successfully demonstrated the feasibility of the proposed strategy using a real-life plastic mixture, yielding various chemical substances such as benzoic acid, plasticizers, and hydrocarbons [7][8]. - The key innovation lies in the universal strategy designed to tackle the challenge of chemical recycling of mixed plastics, allowing for adjustments in chemical steps based on the initial identification of major components [8][10].

Group 1 - The core point of the news is the change in the indirect controlling shareholder of Bluestar Medical, with Langhui Petrochemical acquiring a 52.0395% stake, diluting Bluestar Group's stake from 98% to 47.0013% [1] - The company emphasizes that this equity change does not trigger a mandatory takeover, nor does it lead to a change in the controlling shareholder or actual controller, and it will not adversely affect the company's business structure or financial status [1][2] - Langhui Petrochemical, previously a subsidiary of Bluestar Medical, has maintained a close cooperative relationship with the company, being its largest supplier for three consecutive years from 2022 to 2024 [2][3] Group 2 - Langhui Petrochemical initiated its listing guidance in September 2021, with the latest guidance period set from January 1 to March 31, 2025, but faces challenges in internal control and independent director appointments [3] - Bluestar Medical has experienced continuous pressure on its performance over the past three years, with revenues of 4.9 billion, 4.93 billion, and 6.25 billion from 2022 to 2024, and net profits of -372 million, -568 million, and -445 million during the same period [4] - As of May 28, Bluestar Investment holds 235 million shares of Bluestar Medical, accounting for 23.31%, with 183 million shares pledged, representing 18.2% of the total share capital [4]

Core Viewpoint - The recent change in the shareholding structure of Bluestar Medical has raised concerns among investors regarding potential interests transfer and the implications of the new indirect controlling shareholder, Langhui Chemical [3][4][5] Group 1: Shareholding Changes - Langhui Chemical has acquired a controlling stake in Bluestar Medical's major shareholder, Zibo Bluestar Investment, through a capital increase, diluting the stake of Bluestar Group from 98% to 47.0013% [5][6] - Despite the change in indirect control, the actual controller, Li Zhenping, remains unchanged, and the company asserts that this does not affect the control or business structure of Bluestar Medical [5][6][9] Group 2: Financial Performance and Transactions - Langhui Chemical, previously a loss-making subsidiary, has transformed into a leading enterprise in the plasticizer and resin sector, with revenues of approximately 12.15 billion, 12.69 billion, and 13.42 billion from 2022 to 2024 [6][11] - Bluestar Medical has reported continuous losses over the past three years, with revenues of approximately 4.9 billion, 4.93 billion, and 6.25 billion, and net losses of approximately 372 million, 568 million, and 446 million during the same period [11] Group 3: Supply Chain and Procurement - Langhui Chemical has been the largest supplier for Bluestar Medical over the past three years, with procurement amounts of approximately 499 million, 496 million, and 577 million, accounting for 15.27%, 12.88%, and 12.52% of total annual procurement [9][10] - Bluestar Medical plans to procure approximately 635 million from Langhui Chemical in 2025, which is significantly higher than from other suppliers, indicating a reliance on this supplier despite the commitment to reduce related transactions [10][11]

Core Viewpoint - The report outlines the equity change in Lanfang Medical Co., Ltd. due to Shandong Langhui Petrochemical Co., Ltd. increasing its stake to 52.0395% in Lanfang Investment, resulting in a dilution of Lanfang Group's shareholding from 98% to 47.0013% [1][2][16]. Group 1: Equity Change Details - Shandong Langhui's investment in Lanfang Investment was made through a capital increase, where it converted its debt of RMB 109,096.0961 million into equity [20][21]. - The registered capital of Lanfang Investment increased from RMB 89,600 million to RMB 186,820.4058 million, with RMB 97,220.4058 million allocated to registered capital and RMB 11,875.6903 million to capital reserves [18][19]. - The equity change was executed without any other shareholders exercising their preemptive rights [19]. Group 2: Financial Overview of Shandong Langhui - As of the report date, Shandong Langhui's total assets were RMB 494,725.12 million, with total liabilities of RMB 336,848.50 million, resulting in net assets of RMB 157,876.62 million [10]. - The company's revenue for the year 2024 was RMB 1,341,548.59 million, with a net profit of RMB 21,266.65 million [10]. - The net asset return rate was 13.47%, and the asset-liability ratio stood at 68.09% [10]. Group 3: Business Operations and Independence - Shandong Langhui specializes in the research, production, and sales of fine chemicals, primarily producing plasticizers and PVC resin products [9][12]. - The equity change will not affect Lanfang Medical's independence in operations, assets, personnel, finance, and business [24][25]. - Shandong Langhui has committed to maintaining the independence of Lanfang Medical and avoiding any interference in its operations [24][25]. Group 4: Future Plans and Commitments - Shandong Langhui has no plans to further increase or dispose of its shares in Lanfang Medical within the next 12 months following the equity change [16][22]. - There are no plans for significant adjustments to Lanfang Medical's main business, asset restructuring, or changes in management within the next year [22][23]. - Shandong Langhui has pledged to avoid any competition with Lanfang Medical and its subsidiaries [27][28].

Core Viewpoint - The article discusses the health risks associated with plastic additives, emphasizing the difficulty of completely avoiding plastic in daily life while advocating for informed choices to mitigate exposure risks [1][2]. Group 1: Understanding Plastic Additives - Plastic additives are essential for enhancing the properties of plastics, with 6% of plastic composition being additives, while 94% consists of polymers [2][4]. - Common additives include plasticizers, flame retardants, bisphenol A (BPA), and per- and polyfluoroalkyl substances (PFAS), which are prevalent in everyday products [6][12]. Group 2: Health Risks of Specific Additives - BPA is widely used in polycarbonate plastics and epoxy resins, posing risks such as developmental issues in children and reproductive health problems [7][10]. - Plasticizers, particularly phthalates, are linked to endocrine disruption and various health issues, including obesity and diabetes [9][10]. - Flame retardants, especially halogenated types, can migrate from products into the environment, potentially causing thyroid hormone disruption and neurodevelopmental harm [11][12]. - PFAS are known for their persistence in the environment and human body, associated with liver damage, endocrine disruption, and cancer risks [12][27]. Group 3: Practical Recommendations - To reduce exposure to harmful additives, consumers are advised to check for compliance labels, use products correctly, and avoid plastic containers, especially for food [14][16][17]. - Alternatives to plastic, such as glass, ceramics, and food-grade stainless steel, are recommended to minimize health risks [17].

Core Viewpoint - The market for butanol and isobutanol has experienced significant price declines since January 2024, with butanol prices dropping over 40% and isobutanol prices down approximately 4% year-to-date, indicating ongoing supply-demand challenges in the second quarter [1][2][3]. Group 1: Butanol Market Analysis - Since January 2024, the price of industrial-grade butanol in Shandong has decreased to 6350-6400 RMB per ton, a decline of 9.5% from the beginning of the year [1]. - The first quarter of 2024 saw butanol prices fall from 7025 RMB in early January to around 6600 RMB by the end of March, reflecting a cumulative decline of over 6% [2]. - The butanol market is expected to continue its weak consolidation in the second quarter, with prices projected to fluctuate between 6000-6700 RMB, driven by high operating rates and slow inventory digestion [4]. Group 2: Isobutanol Market Analysis - The isobutanol market also faced downward pressure, with prices fluctuating significantly due to factors such as downstream stocking rhythms and factory inventory strategies [3]. - In early April, isobutanol prices fell below the first quarter's low, indicating a cautious market sentiment and intensified supply-demand negotiations [3]. - The second quarter may see isobutanol prices initially decline before potentially recovering, with projected prices in the range of 7300-7800 RMB, influenced by seasonal demand and supply adjustments [4]. Group 3: Impact of Tariff Wars - The ongoing US-China tariff conflict has had a limited direct impact on the butanol and isobutanol markets due to the relatively small volume of trade between the two countries [5]. - However, the tariff situation has adversely affected exports of certain PVC products, such as gloves, which could indirectly suppress demand for isobutanol, as these products are significant in the downstream consumption of plasticizers [6]. - The export volume of PVC gloves to the US reached 215,300 tons, accounting for over 47% of total exports, which may impact domestic consumption of dioctyl terephthalate (DOTP) and subsequently affect isobutanol demand [6].

Core Viewpoint - The company, Zhejiang Jianye Chemical Co., Ltd., reported a decrease in revenue and net profit for the year 2024, with a focus on its main products in fine chemicals and a proposed cash dividend distribution to shareholders [4][12]. Company Overview - The company primarily produces fine chemical products such as low-carbon fatty amines, electronic chemicals, acetate esters, and plasticizers, which have high added value and wide applications across various industries [5][10]. Financial Performance - In 2024, the company achieved operating revenue of 2.394 billion yuan, a decrease of 9.64% year-on-year, and a net profit attributable to shareholders of 209.06 million yuan, down 34.19% year-on-year [12]. - As of the end of 2024, total assets were 2.603 billion yuan, a decrease of 1.93%, while net assets increased by 3.32% to 2.086 billion yuan [12]. Dividend Proposal - The board of directors proposed a cash dividend of 1.00 yuan per share (including tax), totaling approximately 162.49 million yuan, subject to approval at the 2024 annual general meeting [4]. Industry Insights - The low-carbon fatty amines sector is experiencing stable demand from agriculture and pharmaceuticals, with growth in the renewable energy sector further boosting demand [6]. - The electronic chemicals segment is critical for the electronics industry, with products used in photovoltaic, LED, and semiconductor applications, benefiting from the transfer of production capacity to China [7]. - Acetate esters are widely used as industrial solvents in coatings, inks, and adhesives, with the company focusing on products like n-propyl acetate and isobutyl acetate [9]. - The plasticizer industry, particularly for PVC products, remains a significant application area, with increasing demand in various sectors [10]. Corporate Governance - The company’s board and supervisory board confirmed the authenticity and completeness of the annual report, ensuring compliance with legal and regulatory requirements [3][36].

证券代码：603725 证券简称：天安新材 公告编号：2025-020 广东天安新材料股份有限公司 2024 年度高分子复合饰面材料业务主要经营数据公告 本公告涉及的经营数据已经立信会计师事务所（特殊普通合伙）审计，并为 本公司出具了标准无保留意见的审计报告，详见公司 2025 年 4 月 17 日在上海证 券交易所网站（www.sse.com.cn）披露的公告。有关公司信息均以在指定信息披 露媒体披露的为准，提请广大投资者认真阅读并注意投资风险。 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上市公司自律监管指引第 3 号——行业信息披露第十 三号化工》、《关于做好主板上市公司 2024 年年度报告披露工作的通知》的要 求，广东天安新材料股份有限公司（以下简称"公司"）现将 2024 年度高分子 复合饰面材料业务的主要经营数据披露如下： 二、高分子复合饰面材料主要产品的价格变动情况（不含税） | 主要产品 | 2024 | 年平均售价 | 2023 年平均售价 | | 变动比率（%） | | ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上市公司自律监管指引第 3 号——行业信息披露第十 三号化工》、《关于做好主板上市公司 2025 年第一季度报告披露工作的通知》 的要求，广东天安新材料股份有限公司（以下简称"公司"）现将 2025 年第一 季度高分子复合饰面材料业务的主要经营数据披露如下： 二、高分子复合饰面材料主要产品的价格变动情况（不含税） | 主要产品 | 2025 | 年 1 3 | 至 | 月平均 | 2024 | 年 1 3 | 至 | 月平均 | 变动比率（%） | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 售价 | | | | 售价 | | | | | | 家居装饰饰面材料 | | 23,328.61 | | 元/吨 | | 25,764.45 | | 元/吨 | | -9.45 | | 汽车内饰饰面材料 | | 41,805.64 | | 元/吨 | | 41,54 ...